Nobivac® Canine 1-DAPPv+Cv

Canine Distemper, Adenovirus Type 2, Coronavirus, Parainfluenza, Parvovirus Vaccine, MODIFIED LIVE AND KILLED VIRUS

Proven 1-year combination vaccine that offers broad protection for dogs against parvovirus, coronavirus, distemper, adenovirus types 1 and 2, and parainfluenza.

Features and benefits

  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c1-3
    • Contains CPV-2b, one of the most prevalent field strains of parvovirus
    • High antigenic mass (titer), low passage
    • Multiple studies demonstrate the ability to override maternal antibodies4
  • Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs
  • Provides disease coverage for commonly spread canine viruses, coronavirus, distemper, and parainfluenza, in 1 formula


  • Approved for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper, adenovirus types 1 and 2, parainfluenza, parvovirus, and coronavirus
  • Recommended for use in healthy dogs 6 weeks of age or older

Safety information

Please see the product label for safety information.

Administration and Dosage

  • Subcutaneous or intramuscular injection
  • One 1-mL dose
  • Repeat at 2–4 weeks until dog is 12 weeks old
  • Annual revaccination with 1 dose is recommended: Following the advice of The American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be based upon veterinarian-client patient relationships
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


  1. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101.
  2. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.
  3. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1–2):48–55.
  4. Data on file, Merck Animal Health.